Press coverage about Humana (NYSE:HUM) has trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Humana earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news headlines about the insurance provider an impact score of 46.4902242862136 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Humana Advantage Plan Goes After Florida Plaintiff Lawyer for Failing to Reimburse Conditional Payments Related to Settled Claim (workerscompensation.com)
- Humana: Joint Studies Suggest Relationship Between TV Age Bias and Health of Seniors (diversityinc.com)
- Partners in Primary Care to Open Senior-focused Medical Center in Gastonia (finance.yahoo.com)
- Humana, Inc. breached its 50 day moving average in a Bearish Manner : HUM-US : September 20, 2017 (finance.yahoo.com)
- Cowen and Company Reaffirms “Outperform” Rating for Humana Inc. (HUM) (americanbankingnews.com)
HUM has been the subject of several research analyst reports. Zacks Investment Research lowered shares of Humana from a “buy” rating to a “hold” rating in a research note on Tuesday, May 23rd. Leerink Swann lifted their price objective on shares of Humana from $250.00 to $265.00 and gave the company an “outperform” rating in a research note on Tuesday, May 30th. Royal Bank Of Canada reiterated a “hold” rating and issued a $214.00 price objective on shares of Humana in a research note on Monday, June 5th. Morgan Stanley initiated coverage on shares of Humana in a research note on Tuesday, June 6th. They issued an “overweight” rating and a $262.00 price objective for the company. Finally, Argus upgraded shares of Humana from a “hold” rating to a “buy” rating and set a $260.00 price objective for the company in a research note on Friday, June 9th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. Humana has a consensus rating of “Buy” and an average price target of $246.60.
Humana (NYSE:HUM) traded down 0.15% on Wednesday, hitting $239.68. 1,824,163 shares of the company traded hands. The firm’s 50 day moving average price is $250.95 and its 200 day moving average price is $232.23. The firm has a market capitalization of $34.64 billion, a PE ratio of 19.72 and a beta of 0.87. Humana has a 1-year low of $163.50 and a 1-year high of $259.76.
Humana (NYSE:HUM) last issued its earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.08 by $0.41. The company had revenue of $13.53 billion for the quarter, compared to the consensus estimate of $13.61 billion. Humana had a return on equity of 15.85% and a net margin of 3.37%. During the same quarter last year, the company earned $2.30 EPS. Equities research analysts predict that Humana will post $11.55 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Tuesday, August 29th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date is Thursday, September 28th. Humana’s payout ratio is 13.06%.
In other Humana news, VP M Todoroff Christopher sold 22,935 shares of Humana stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $252.52, for a total value of $5,791,546.20. Following the sale, the vice president now owns 24,001 shares of the company’s stock, valued at approximately $6,060,732.52. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Timothy S. Huval sold 7,803 shares of Humana stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $258.14, for a total value of $2,014,266.42. Following the completion of the sale, the vice president now directly owns 8,831 shares in the company, valued at approximately $2,279,634.34. The disclosure for this sale can be found here. In the last ninety days, insiders sold 60,566 shares of company stock worth $15,326,746. Corporate insiders own 0.80% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://transcriptdaily.com/2017/09/21/humana-hum-getting-somewhat-positive-news-coverage-analysis-finds.html.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.